دورية أكاديمية
[Dissolution and maintenance of portal vein thrombosis with antithrombin III and edoxaban in liver cirrhosis:a case report].
العنوان: | [Dissolution and maintenance of portal vein thrombosis with antithrombin III and edoxaban in liver cirrhosis:a case report]. |
---|---|
المؤلفون: | Eto H; Department of Gastroenterology, Fukaya Red Cross Hospital., Kawabe K; Department of Gastroenterology, Fukaya Red Cross Hospital., Kasai T; Department of Gastroenterology, Fukaya Red Cross Hospital., Muramatsu S; Department of Gastroenterology, Fukaya Red Cross Hospital., Miyahara Y; Department of Gastroenterology, Fukaya Red Cross Hospital., Nakahara M; Department of Gastroenterology, Fukaya Red Cross Hospital., Fukuda H; Department of Gastroenterology, Fukaya Red Cross Hospital., Imai T; Department of Gastroenterology, Fukaya Red Cross Hospital., Ito H; Department of Surgery, Fukaya Red Cross Hospital. |
المصدر: | Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology [Nihon Shokakibyo Gakkai Zasshi] 2019; Vol. 116 (6), pp. 523-530. |
نوع المنشور: | Case Reports; Journal Article |
اللغة: | Japanese |
بيانات الدورية: | Publisher: Japanese Society Of Gastroenterology Country of Publication: Japan NLM ID: 2984683R Publication Model: Print Cited Medium: Print ISSN: 0446-6586 (Print) Linking ISSN: 04466586 NLM ISO Abbreviation: Nihon Shokakibyo Gakkai Zasshi |
أسماء مطبوعة: | Original Publication: Tokyo : Japanese Society Of Gastroenterology |
مواضيع طبية MeSH: | Portal Vein*, Anticoagulants/*therapeutic use , Antithrombin III/*therapeutic use , Liver Cirrhosis/*complications , Pyridines/*therapeutic use , Thiazoles/*therapeutic use , Thrombosis/*drug therapy, Aged ; Humans ; Male ; Solubility |
مستخلص: | A male patient in his 70s was referred to our department. He was found to have alcoholic liver cirrhosis, esophageal varices, and portal vein thrombosis. Antithrombin III (ATIII) formulation was administered. The thrombus was almost completely lysed 2 days after administration. Because portal vein thrombosis could recur, edoxaban, a direct oral anticoagulant (DOAC), was introduced to prevent recurrence. After 4 months, he showed no recurrence of portal vein thrombosis. In the present case, the combination of an ATIII formulation as initial treatment and edoxaban as maintenance therapy was safe and effective. The combination of ATIII and edoxaban may be a treatment option for patients with portal vein thrombosis. |
المشرفين على المادة: | 0 (Anticoagulants) 0 (Pyridines) 0 (Thiazoles) 9000-94-6 (Antithrombin III) NDU3J18APO (edoxaban) |
تواريخ الأحداث: | Date Created: 20190611 Date Completed: 20190807 Latest Revision: 20200928 |
رمز التحديث: | 20231215 |
DOI: | 10.11405/nisshoshi.116.523 |
PMID: | 31178582 |
قاعدة البيانات: | MEDLINE |
تدمد: | 0446-6586 |
---|---|
DOI: | 10.11405/nisshoshi.116.523 |